PDCD1 and non-small cell lung carcinoma: Considering the different role of PD-1 inhibitors in NSCLC patients with varying clinical and molecular features, this rare case report represents an important update demonstrating that therapy with a PD-1-blocking antibody and autologous CIK cells is well tolerated.